Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 20/20 | 0.66 |
| ▸ | PIK3R1 | P27986 | 10/20 | 0.66 |
| ▸ | MTOR | P42345 | 10/20 | 0.66 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.49 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.48 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.48 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.48 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.47 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.47 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.47 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10328260 | 0.85 | PIK3CA (0.60) | PIK3CAPIK3R1MTORPIK3CDRICTOR | |
| SCHEMBL14468789 | 0.83 | PIK3CA (0.62) | PIK3CAPIK3R1MTORPIK3CDRICTOR | |
| SCHEMBL1310736 | 0.80 | PIK3CA (1.00) | PIK3CAPIK3R1MTORPIK3CDRICTOR | |
| SCHEMBL10328135 | 0.79 | PIK3CA (0.66) | PIK3CAPIK3R1MTORPIK3CDRICTOR | |
| SCHEMBL16639078 | 0.77 | PIK3CA (0.65) | PIK3CAPIK3R1MTORPIK3CDRICTOR | |
| SCHEMBL20725700 | 0.76 | PIK3CA (0.63) | PIK3CAPIK3R1MTORPIK3CDRICTOR | |
| SCHEMBL18117893 | 0.76 | PIK3CA (0.90) | PIK3CAPIK3R1MTORPIK3CDRICTOR | |
| SCHEMBL1309060 | 0.76 | PIK3CA (0.90) | PIK3CAPIK3R1MTORPIK3CDRICTOR | |
| SCHEMBL10327870 | 0.75 | PIK3CA (0.68) | PIK3CAPIK3R1MTORPIK3CDRICTOR | |
| SCHEMBL1311181 | 0.75 | PIK3CA (0.88) | PIK3CAPIK3R1MTORPIK3CDRICTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563549-B2 | Pyrimidine derivatives used as PI-3 kinase inhibitors | NOVARTIS AG (CH) | 2013-10-22 | — | — | US | disclosed |
| US-8563549-B2 | Pyrimidine derivatives used as PI-3 kinase inhibitors | NOVARTIS AG (CH) | 2013-10-22 | — | — | US | disclosed |
| EP-2261223-B1 | Pyrimidine derivatives used as pi-3 kinase inhibitors | NOVARTIS AG (CH) | 2013-06-12 | — | — | EP | disclosed |
| US-20120225859-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-09-06 | — | — | US | disclosed |
| US-20120225859-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-09-06 | — | — | US | disclosed |
| US-8217035-B2 | Pyrimidine derivatives used as PI-3-kinase inhibitors | NOVARTIS AG (CH) | 2012-07-10 | — | — | US | disclosed |
| US-8217035-B2 | Pyrimidine derivatives used as PI-3-kinase inhibitors | NOVARTIS AG (CH) | 2012-07-10 | — | — | US | disclosed |
| EP-2261223-A1 | Pyrimidine derivatives used as pi-3 kinase inhibitors | Novartis AG (CH) | 2010-12-15 | — | — | EP | disclosed |
| US-20100249126-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3-KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249126-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3-KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2010-09-30 | — | — | US | disclosed |
| EP-1984350-B1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249126-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3-KINASE INHIBITORS | PIK3CA, PI4KA, PI4KB | PIK3CA 1/4885PIK3R1 51/4885MTOR 62/4885 |
| US-20120225859-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | PIK3CA, PI4KA, PI4KB | PIK3CA 1/4885PIK3R1 44/4885MTOR 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.